Intraocular Pressure Reduction In Open Angle Glaucoma Or Ocular Hypertension Therapeutics
1. Vyzulta patent expiration
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
VYZULTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6211233 | BAUSCH AND LOMB | Prostaglandin pharmaceutical compositions |
Jun, 2018
(7 years ago) | |
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Feb, 2029
(3 years from now) | |
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 3 days ago) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 3 days ago) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Dosage: SOLUTION/DROPS
How can I launch a generic of VYZULTA before it's drug patent expiration?
More Information on Dosage
VYZULTA family patents
